Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Blue Moon Group Holdings / Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/guangzhou-blue-moon-industry-co-ltd" target="_blank" data-smartkarma-citation="entities:29179:1" rel="noopener">Blue Moon Group Holdings (BMG HK)</a> (BMG) raised around US$1.4bn in its Hong Kong listing. The company is backed by Hillhouse who first invested in the company in 2010. </p></div><div><p>We have covered various aspects of the deal, in our earlier insights:</p></div><div><ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-the-positives-dominant-market-share-strong-online-sales" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - The Positives - Dominant Market Share, Strong Online Sales</a></li>
<li>In <a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-the-negatives-flagging-offline-sales-not-really-a-primary-raising" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - The Negatives - Flagging Offline Sales, Not Really a Primary Raising</a>
</li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-no-1-but-no-exclusive-advantage-observation-on-the-ground" target="_blank" rel="noopener">Blue Moon: No. 1 but no exclusive advantage, observation on the ground.</a></li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-online-reviews-and-peer-comparison" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - Online Reviews and Peer Comparison</a></li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-initial-thoughts-on-valuation" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - Initial Thoughts on Valuation</a></li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-phip-updates-a-mixed-bag" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - PHIP Updates - A Mixed Bag</a></li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-pre-ipo-valuation-updates" target="_blank" rel="noopener">Blue Moon Group Pre-IPO - Valuation Updates</a></li>
<li><a href="https://www.smartkarma.com/insights/blue-moon-group-ipo-not-a-clean-wash" target="_blank" rel="noopener">Blue Moon Group IPO - Not a Clean Wash</a></li>
</ul></div><div><p>In this insight, I'll talk about the subscription levels and provide a table with implied valuations.</p></div>

Blue Moon Group Holdings (BMG HK) (BMG) raised around US$1.4bn in its Hong Kong listing. The company is backed by Hillhouse who first invested in the company in 2010. We have covered various aspects of the deal, in our earlier insights:
Blue Moon Group Pre-IPO - The Positives - Dominant Market Share, Strong Online Sales
In Blue Moon Group Pre-IPO - The Negatives - Flagging Offline Sales, Not Really a Primary Raising

Blue Moon: No. 1 but no exclusive advantage, observation on the ground.
Blue Moon Group Pre-IPO - Online Reviews and Peer Comparison
Blue Moon Group Pre-IPO - Initial Thoughts on Valuation
Blue Moon Group Pre-IPO - PHIP Updates - A Mixed Bag
Blue Moon Group Pre-IPO - Valuation Updates
Blue Moon Group IPO - Not a Clean Wash
In this insight, I'll talk about the subscription levels and provide a table with implied valuations.

Blue Moon Group IPO Trading - Too Expensive for Our Liking but Retail Traders Seem to Like It

Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

Cafe De Coral Holdings / Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/cafe-de-coral-holdings-ltd" target="_blank" data-smartkarma-citation="entities:2568:1" rel="noopener">Cafe De Coral Holdings (341 HK)</a> business in Hong Kong and China are recovering nicely due to the calming down of the COVID-19 as well as the strategy change to focus on the delivery and take away markets. One of the key initiatives is to redesign the menu offering so that it is more suitable for the delivery and take away customers. However, empirical evidence tells that the company is yet to reach a popular status in one of the food delivery apps in Hong Kong which is quite worrying. </p>
<p>The recent dining restrictions do not seem to bother investors much at all therefore there is still an opportunity to <strong>short Cafe de Coral</strong> in the short run. </p>

Cafe De Coral Holdings (341 HK) business in Hong Kong and China are recovering nicely due to the calming down of the COVID-19 as well as the strategy change to focus on the delivery and take away markets. One of the key initiatives is to redesign the menu offering so that it is more suitable for the delivery and take away customers. However, empirical evidence tells that the company is yet to reach a popular status in one of the food delivery apps in Hong Kong which is quite worrying. 
The recent dining restrictions do not seem to bother investors much at all therefore there is still an opportunity to short Cafe de Coral in the short run. 

Cafe De Coral (341): Still Unfazed by the New Restriction

Pop Mart International Group L / Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/pop-mart-international-group-limited" target="_blank" data-smartkarma-citation="entities:29016:1" rel="noopener">POP MART (POP HK)</a> raised around US$775m in its Hong Kong IPO. Pop Mart (PM) is the largest and fastest growing pop toy company in China, in terms of 2019 revenue and revenue CAGR over 2017-19. PM had a 8.5% market share by retail value, making it the largest player in the pop toy retailing market.</p></div><div><p>In our previous insights, we spoke about the various aspects of the deal: </p></div><div><ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-the-positives-expanding-portfolio-wider-distribution-explosive-earnings-growth" target="_blank" rel="noopener">Pop Mart Pre-IPO - The Positives - Expanding Portfolio+Wider Distribution= Explosive Earnings Growth,</a> and</li>
<li><a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-the-negatives-is-it-a-brand-owner-or-just-a-retailer" target="_blank" rel="noopener">Pop Mart Pre-IPO - The Negatives - Is It a Brand Owner or Just a Retailer?</a></li>
<li><a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-peer-set-and-valuation" target="_blank" data-smartkarma-citation="insights:41850" rel="noopener">Pop Mart Pre-IPO - Peer Set and Valuation</a></li>
<li><a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-quick-note-on-the-ground-pop-up-stores-are-effective" target="_blank" rel="noopener">Pop Mart Pre-IPO Quick Note - On the Ground - Pop-Up Stores Are Effective</a></li>
</ul></div><div><ul style="list-style-type: disc;"><li><a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-phip-updates-still-riding-on-past-expansion" target="_blank" rel="noopener">Pop Mart Pre-IPO - PHIP Updates - Still Riding on past Expansion</a></li></ul></div><div><ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/pop-mart-pre-ipo-valuation-updates" target="_blank" rel="noopener">Pop Mart Pre-IPO - Valuation Updates</a></li>
<li><a href="https://www.smartkarma.com/insights/pop-mart-ipo-making-you-pay-well-for-growth" target="_blank" rel="noopener">Pop Mart IPO - Making You Pay Well for Growth</a></li>
</ul></div><p>In this insight, I'll talk about the subscription levels and provide a table with implied valuations.</p>

POP MART (POP HK) raised around US$775m in its Hong Kong IPO. Pop Mart (PM) is the largest and fastest growing pop toy company in China, in terms of 2019 revenue and revenue CAGR over 2017-19. PM had a 8.5% market share by retail value, making it the largest player in the pop toy retailing market.In our previous insights, we spoke about the various aspects of the deal: 

Pop Mart Pre-IPO - The Positives - Expanding Portfolio+Wider Distribution= Explosive Earnings Growth, and
Pop Mart Pre-IPO - The Negatives - Is It a Brand Owner or Just a Retailer?
Pop Mart Pre-IPO - Peer Set and Valuation
Pop Mart Pre-IPO Quick Note - On the Ground - Pop-Up Stores Are Effective
Pop Mart Pre-IPO - PHIP Updates - Still Riding on past Expansion
Pop Mart Pre-IPO - Valuation Updates
Pop Mart IPO - Making You Pay Well for Growth
In this insight, I'll talk about the subscription levels and provide a table with implied valuations.

Pop Mart IPO Trading - Set for a Pop but We Won't Be Chasing

APAC IPOs & Placements

Zhen Zhou, Toh

JD Health International  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/jd-health-international" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.</p>
<p>JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. </p>
<p>In this note, we will look at the deal dynamics and provide a table with implied valuation at different share price levels.</p>
<p>We have previously covered the IPO extensively:</p>
<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-well-positioned-to-ride-china-s-healthcare-digitalization" target="_blank" data-smartkarma-citation="insights:43711" rel="noopener">JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-peer-comparison-it-s-a-close-fight-and-competition-is-intensifying" target="_blank" data-smartkarma-citation="insights:45062" rel="noopener">JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-assumptions-and-valuations" target="_blank" data-smartkarma-citation="insights:45266" rel="noopener">JD Health (京东健康) Pre-IPO - Assumptions and Valuations</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-updates-from-phip-fine-tuning-forecasts" target="_blank" data-smartkarma-citation="insights:45368" rel="noopener">JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-paying-to-ride-the-early-innings-of-healthcare-transformation" target="_blank" data-smartkarma-citation="insights:45695" rel="noopener">JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-ali-health-1h-results-read-through-and-index-inclusions" target="_blank" data-smartkarma-citation="insights:45773" rel="noopener">JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions</a> </li>
</ul>

JD Health (6618 HK) raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.
JDH’s retail pharmacy and online healthcare services form a strong, closed loop, end-to-end healthcare ecosystem that is well-positioned to benefit from the digitalization of China’s healthcare system. It has an extensive network of online and offline pharmacies which is expanding into offering more online healthcare services. 
In this note, we will look at the deal dynamics and provide a table with implied valuation at different share price levels.
We have previously covered the IPO extensively:


JD Health (京东健康) Pre-IPO - Well-Positioned to Ride China’s Healthcare Digitalization 

JD Health (京东健康) Pre-IPO - Peer Comparison - It's a Close Fight and Competition Is Intensifying 

JD Health (京东健康) Pre-IPO - Assumptions and Valuations 

JD Health (京东健康) Pre-IPO - Updates from PHIP - Fine-Tuning Forecasts 

JD Health (京东健康) IPO - Paying to Ride the Early Innings of Healthcare Transformation 

JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions 


JD Health (京东健康) IPO Trading - Looking to Be a Solid Debut

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

Hansoh Pharmaceutical Group  / Event-Driven

<p>The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 13 November. The constituent changes will be effective after the close of trading on 4 December.</p><p>For the <a href="https://www.smartkarma.com/entities/hang-seng-china-enterprises-index" target="_blank" data-smartkarma-citation="entities:22900:1" rel="noopener">Hang Seng China Enterprises Index (HSCEI INDEX)</a>, there are 9 inclusions and 9 deletions.</p><p>The inclusions are <a href="https://www.smartkarma.com/entities/alibaba-health-information-technology-ltd" target="_blank" data-smartkarma-citation="entities:453:1" rel="noopener">Alibaba Health Information Technology (241 HK)</a>, <a href="https://www.smartkarma.com/entities/china-overseas-land-invest" target="_blank" data-smartkarma-citation="entities:419:1" rel="noopener">China Overseas Land &amp; Investment Ltd (688 HK)</a>, <a href="https://www.smartkarma.com/entities/semiconductor-manufacturing-international-corp-smic" target="_blank" data-smartkarma-citation="entities:14231:1" rel="noopener">Semiconductor Manufacturing International Corp (SMIC) (981 HK)</a>, <a href="https://www.smartkarma.com/entities/evergrande-real-estate-group-limited" target="_blank" data-smartkarma-citation="entities:479:1" rel="noopener">Evergrande Real Estate Group (3333 HK)</a>, <a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical (3692 HK)</a>, <a href="https://www.smartkarma.com/entities/china-feihe-ltd" target="_blank" data-smartkarma-citation="entities:24413:1" rel="noopener">China Feihe (6186 HK)</a>, <a href="https://www.smartkarma.com/entities/haidilao-international-holding-ltd" target="_blank" data-smartkarma-citation="entities:27044:1" rel="noopener">Haidilao (6862 HK)</a>, <a href="https://www.smartkarma.com/entities/jd-com-inc" target="_blank" data-smartkarma-citation="entities:29043:1" rel="noopener">JD.com (HK) (9618 HK)</a> and <a href="https://www.smartkarma.com/entities/netease" target="_blank" data-smartkarma-citation="entities:29030:1" rel="noopener">NetEase (9999 HK)</a>. </p><p>The deletions are <a href="https://www.smartkarma.com/entities/want-want-china-holdings-ltd" target="_blank" data-smartkarma-citation="entities:355:1" rel="noopener">Want Want (151 HK)</a>, <a href="https://www.smartkarma.com/entities/fosun-international-ltd" target="_blank" data-smartkarma-citation="entities:433:1" rel="noopener">Fosun International (656 HK)</a>, <a href="https://www.smartkarma.com/entities/china-telecom-corp-ltd-h" target="_blank" data-smartkarma-citation="entities:1015:1" rel="noopener">China Telecom Corp Ltd (H) (728 HK)</a>, <a href="https://www.smartkarma.com/entities/china-taiping-insurance-hldgs-co-ltd" target="_blank" data-smartkarma-citation="entities:489:1" rel="noopener">China Taiping Insurance Hldgs (966 HK)</a>, <a href="https://www.smartkarma.com/entities/china-citic-bank-corp-ltd-ea6c25fd-4b20-45cb-a4a6-df7a60136f03" target="_blank" data-smartkarma-citation="entities:653:1" rel="noopener">China Citic Bank Corp Ltd H (998 HK)</a>, <a href="https://www.smartkarma.com/entities/china-shenhua-energy-co-h" target="_blank" data-smartkarma-citation="entities:382:1" rel="noopener">China Shenhua Energy Co H (1088 HK)</a>, <a href="https://www.smartkarma.com/entities/china-minsheng-banking-h" target="_blank" data-smartkarma-citation="entities:8983:1" rel="noopener">China Minsheng Banking H (1988 HK)</a>, <a href="https://www.smartkarma.com/entities/china-vanke-co-ltd-h" target="_blank" data-smartkarma-citation="entities:18368:1" rel="noopener">China Vanke Co Ltd (H) (2202 HK)</a> and <a href="https://www.smartkarma.com/entities/picc-property-casualty-h" target="_blank" data-smartkarma-citation="entities:350:1" rel="noopener">PICC Property &amp; Casualty H (2328 HK)</a>. </p><p>One-way turnover is estimated at 10.21% and volumes at the closing auction on 4 December are going to be HUGE. Passive funds will need to trade between 1.5-4.5 days of ADV on the deletions and between 0.5-4 days of ADV on the inclusions.</p><p>We had picked all 9 inclusions and exclusions, so there are no surprises in the review. That said, the probability of <a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical (3692 HK)</a> being included was the lowest since it was right at the cusp of inclusion, so there could be a pop at the open on Monday. Hansoh, at almost 4 days of ADV, has the biggest impact to buy from passive funds. The corresponding deletion was <a href="https://www.smartkarma.com/entities/picc-property-casualty-h" target="_blank" data-smartkarma-citation="entities:350:1" rel="noopener">PICC Property &amp; Casualty H (2328 HK)</a> and the stock could start trading lower on Monday.</p>

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 13 November. The constituent changes will be effective after the close of trading on 4 December.For the Hang Seng China Enterprises Index (HSCEI INDEX), there are 9 inclusions and 9 deletions.The inclusions are Alibaba Health Information Technology (241 HK), China Overseas Land &amp; Investment Ltd (688 HK), Semiconductor Manufacturing International Corp (SMIC) (981 HK), Evergrande Real Estate Group (3333 HK), Hansoh Pharmaceutical (3692 HK), China Feihe (6186 HK), Haidilao (6862 HK), JD.com (HK) (9618 HK) and NetEase (9999 HK). The deletions are Want Want (151 HK), Fosun International (656 HK), China Telecom Corp Ltd (H) (728 HK), China Taiping Insurance Hldgs (966 HK), China Citic Bank Corp Ltd H (998 HK), China Shenhua Energy Co H (1088 HK), China Minsheng Banking H (1988 HK), China Vanke Co Ltd (H) (2202 HK) and PICC Property &amp; Casualty H (2328 HK). One-way turnover is estimated at 10.21% and volumes at the closing auction on 4 December are going to be HUGE. Passive funds will need to trade between 1.5-4.5 days of ADV on the deletions and between 0.5-4 days of ADV on the inclusions.We had picked all 9 inclusions and exclusions, so there are no surprises in the review. That said, the probability of Hansoh Pharmaceutical (3692 HK) being included was the lowest since it was right at the cusp of inclusion, so there could be a pop at the open on Monday. Hansoh, at almost 4 days of ADV, has the biggest impact to buy from passive funds. The corresponding deletion was PICC Property &amp; Casualty H (2328 HK) and the stock could start trading lower on Monday.

HSCEI Index Rebalance: 9 Adds, 9 Deletes, BIG Turnover

China

Haidilao International Holding Ltd. operates Chinese cuisine restaurant brand focusing on hot pot cuisine. The Company provides hot pots, soup bases, dipping sauces, drinks, prepared food, and other products. Haidilao International Holding opens restaurants in Taiwan, Hong Kong, Singapore, South Korea, Japan, and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Haidilao International Holding (6862 HK)

Blue Moon Group IPO Trading - Too Expensive for Our Liking but Retail Traders Seem to Like It

Blue Moon Group Holdings (BMG HK) (BMG) raised around US$1.4bn in its Hong Kong listing. The company is backed by Hillhouse who first invested in...

Sumeet Singh

Cafe De Coral (341): Still Unfazed by the New Restriction

The recent dining restrictions do not seem to bother investors much at all therefore there is still an opportunity to short Cafe de Coral in the...

Henry Soediarko

Pop Mart IPO Trading - Set for a Pop but We Won't Be Chasing

POP MART raised around US$775m in its Hong Kong IPO. Pop Mart is the largest and fastest growing pop toy company in China, in terms of 2019 revenue...

Sumeet Singh

JD Health (京东健康) IPO Trading - Looking to Be a Solid Debut

JD Health (6618 HK) raised US$3.5bn in its Hong Kong IPO, priced at HK$70.58 per share, at the top-end of its price range.

Zhen Zhou, Toh

HSCEI Index Rebalance: 9 Adds, 9 Deletes, BIG Turnover

There are 9 adds and 9 deletes in the upcoming HSCEI rebalance. Turnover at 10%+ is big and there is a lot of short interest on names. The momentum...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)